Cargando…

Delayed fractional dose regimen of the RTS,S/AS01 malaria vaccine candidate enhances an IgG4 response that inhibits serum opsonophagocytosis

A recent study of the RTS,S malaria vaccine, which is based on the circumsporozoite protein (CSP), demonstrated an increase in efficacy from 50–60% to 80% when using a delayed fractional dose regimen, in which the standard 0–1–2 month immunization schedule was modified to a 0–1–7 month schedule and...

Descripción completa

Detalles Bibliográficos
Autores principales:	Chaudhury, Sidhartha, Regules, Jason A., Darko, Christian A., Dutta, Sheetij, Wallqvist, Anders, Waters, Norman C., Jongert, Erik, Lemiale, Franck, Bergmann-Leitner, Elke S.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group UK 2017
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5554171/ https://www.ncbi.nlm.nih.gov/pubmed/28801554 http://dx.doi.org/10.1038/s41598-017-08526-5

Ejemplares similares

The biological function of antibodies induced by the RTS,S/AS01 malaria vaccine candidate is determined by their fine specificity
por: Chaudhury, Sidhartha, et al.
Publicado: (2016)

A delayed fractionated dose RTS,S AS01 vaccine regimen mediates protection via improved T follicular helper and B cell responses
por: Pallikkuth, Suresh, et al.
Publicado: (2020)

A Phase IIa Controlled Human Malaria Infection and Immunogenicity Study of RTS,S/AS01(E) and RTS,S/AS01(B) Delayed Fractional Dose Regimens in Malaria-Naive Adults
por: Moon, James E, et al.
Publicado: (2020)

Role of Opsonophagocytosis in Immune Protection against Malaria
por: Leitner, Wolfgang W., et al.
Publicado: (2020)

Comprehensive Data Integration Approach to Assess Immune Responses and Correlates of RTS,S/AS01-Mediated Protection From Malaria Infection in Controlled Human Malaria Infection Trials
por: Young, William Chad, et al.
Publicado: (2021)

Comparison of ELISA with electro-chemiluminescence technology for the qualitative and quantitative assessment of serological responses to vaccination
por: Bolton, Jessica S., et al.
Publicado: (2020)

Effect of the Pre-erythrocytic Candidate Malaria Vaccine RTS,S/AS01(E) on Blood Stage Immunity in Young Children
por: Bejon, Philip, et al.
Publicado: (2011)

Combining immunoprofiling with machine learning to assess the effects of adjuvant formulation on human vaccine-induced immunity
por: Chaudhury, Sidhartha, et al.
Publicado: (2019)

Protective antibody threshold of RTS,S/AS01 malaria vaccine correlates antigen and adjuvant dose in mouse model
por: Genito, Christopher J., et al.
Publicado: (2023)

The thermostability of the RTS,S/AS01 malaria vaccine can be increased by co-lyophilizing RTS,S and AS01
por: Fortpied, Juliette, et al.
Publicado: (2020)

Avidity of Anti-Circumsporozoite Antibodies following Vaccination with RTS,S/AS01(E) in Young Children
por: Olotu, Ally, et al.
Publicado: (2014)

Ad35.CS.01 - RTS,S/AS01 Heterologous Prime Boost Vaccine Efficacy against Sporozoite Challenge in Healthy Malaria-Naïve Adults
por: Ockenhouse, Christian F., et al.
Publicado: (2015)

T Cell Responses to the RTS,S/AS01(E) and RTS,S/AS02(D) Malaria Candidate Vaccines Administered According to Different Schedules to Ghanaian Children
por: Ansong, Daniel, et al.
Publicado: (2011)

Induction of Plasmodium falciparum-Specific CD4(+) T Cells and Memory B Cells in Gabonese Children Vaccinated with RTS,S/AS01(E) and RTS,S/AS02(D)
por: Agnandji, Selidji T., et al.
Publicado: (2011)

Computational and Experimental Validation of B and T-Cell Epitopes of the In Vivo Immune Response to a Novel Malarial Antigen
por: Bergmann-Leitner, Elke S., et al.
Publicado: (2013)

Correlations between three ELISA protocols measurements of RTS,S/AS01-induced anti-CSP IgG antibodies
por: Mugo, Robert M., et al.
Publicado: (2023)

Effect of ingested human antibodies induced by RTS, S/AS01 malaria vaccination in children on Plasmodium falciparum oocyst formation and sporogony in mosquitoes
por: Miura, Kazutoyo, et al.
Publicado: (2014)

Evaluation of RTS,S/AS02A and RTS,S/AS01B in Adults in a High Malaria Transmission Area
por: Polhemus, Mark E., et al.
Publicado: (2009)

Mosquirix™ RTS, S/AS01 Vaccine Development, Immunogenicity, and Efficacy
por: Nadeem, Aroosa Younis, et al.
Publicado: (2022)

Transcriptional correlates of malaria in RTS,S/AS01-vaccinated African children: a matched case–control study
por: Moncunill, Gemma, et al.
Publicado: (2022)

Circumsporozoite-Specific T Cell Responses in Children Vaccinated with RTS,S/AS01(E) and Protection against P falciparum Clinical Malaria
por: Olotu, Ally, et al.
Publicado: (2011)

Assessing Prevalence and Transmission Rates of Malaria through Simultaneous Profiling of Antibody Responses against Plasmodium and Anopheles Antigens
por: Chaudhury, Sidhartha, et al.
Publicado: (2022)

A Statistical Interaction between Circumsporozoite Protein-Specific T Cell and Antibody Responses and Risk of Clinical Malaria Episodes following Vaccination with RTS,S/AS01E
por: Ndungu, Francis M., et al.
Publicado: (2012)

Characterization of T-cell immune responses in clinical trials of the candidate RTS,S malaria vaccine
por: Moris, Philippe, et al.
Publicado: (2017)

The Future of the RTS,S/AS01 Malaria Vaccine: An Alternative Development Plan
por: Gosling, Roly, et al.
Publicado: (2016)

A monoclonal antibody-based immunoassay to measure the antibody response against the repeat region of the circumsporozoite protein of Plasmodium falciparum
por: Radin, Kristina, et al.
Publicado: (2016)

Implementation strategies for the introduction of the RTS,S/AS01 (RTS,S) malaria vaccine in countries with areas of highly seasonal transmission: workshop meeting report
por: Merle, Corinne S.
Publicado: (2023)

Differential Patterns of IgG Subclass Responses to Plasmodium falciparum Antigens in Relation to Malaria Protection and RTS,S Vaccination
por: Dobaño, Carlota, et al.
Publicado: (2019)

Environmental modifiers of RTS,S/AS01 malaria vaccine efficacy in Lilongwe, Malawi
por: Bell, Griffin J., et al.
Publicado: (2020)

Towards Eradication of Malaria: Is the WHO’s RTS,S/AS01 Vaccination Effective Enough?
por: Arora, Navneet, et al.
Publicado: (2021)

Should India be considering deployment of the first malaria vaccine RTS, S/AS01?
por: Rahi, Manju, et al.
Publicado: (2022)

RTS,S/AS01 Malaria Vaccine - The Next Step for a Developing Country
por: ZEHRA, ASMAT, et al.
Publicado: (2022)

RTS,S/AS01 malaria vaccine (Mosquirix(®)): a profile of its use
por: Syed, Yahiya Y.
Publicado: (2022)

Acceptance, availability, and feasibility of RTS, S/AS01 malaria vaccine: A review
por: Mumtaz, Hassan, et al.
Publicado: (2023)

IgG Endopeptidase SeMac does not Inhibit Opsonophagocytosis of Streptococcus equi Subspecies equi by Horse Polymorphonuclear Leukocytes
por: Liu, Mengyao, et al.
Publicado: (2010)

Antibody responses to the RTS,S/AS01(E) vaccine and Plasmodium falciparum antigens after a booster dose within the phase 3 trial in Mozambique
por: Sánchez, Lina, et al.
Publicado: (2020)

Immune Adherence–mediated Opsonophagocytosis: The Mechanism of Leishmania Infection
por: Domínguez, Mercedes, et al.
Publicado: (1999)

Impact of RTS,S/AS02(A) and RTS,S/AS01(B) on Genotypes of P. falciparum in Adults Participating in a Malaria Vaccine Clinical Trial
por: Waitumbi, John N., et al.
Publicado: (2009)

Circulating follicular T helper cells and cytokine profile in humans following vaccination with the rVSV-ZEBOV Ebola vaccine
por: Farooq, Fouzia, et al.
Publicado: (2016)

The effect of immunization schedule with the malaria vaccine candidate RTS,S/AS01(E) on protective efficacy and anti-circumsporozoite protein antibody avidity in African infants
por: Ajua, Anthony, et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_6iaj6m2gre7320of32rho7oi3h